Retraction note
This article has been retracted by the authors after discovering an error in the data. The two CATIE-AD articles included in the systematic review [1, 2] should not have been treated as separate trials as this led to data from some trial participants being included twice in the meta-analysis. As a result, large sections of the article are inaccurate. To avoid confusion this article has been retracted and the authors have been given the opportunity to resubmit their corrected data.
[1] Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355:1525-38.
[2] Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165:844-54.
Footnotes
The online version of the original article can be found under doi:10.1186/s13195-015-0102-9.
Contributor Information
Lan Tan, Email: dr.tanlan@163.com.
Jin-Tai Yu, Email: yu-jintai@163.com.
References
- 1.Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355:1525–38. doi: 10.1056/NEJMoa061240. [DOI] [PubMed] [Google Scholar]
- 2.Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165:844–54. doi: 10.1176/appi.ajp.2008.07111779. [DOI] [PMC free article] [PubMed] [Google Scholar]